Innovita and its wholly-owned subsidiary Tangshan Innovita have newly obtained three product certifications and completed one medical device change registration for a combined respiratory syncytial virus and adenovirus antigen test kit. The acquisition of these certifications will broaden the company's product range, enhance its market expansion capabilities, and strengthen its core competitiveness. In the first quarter of 2026, Innovita achieved revenue of 109 million yuan and a net profit attributable to the parent company of 40.63 million yuan.
Innovita Biological Technology Co. Ltd. AObtained three product certifications and one medical device change registration, broadening product range and enhancing competitiveness.
